We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
-17.1%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$5.69B
AUM Growth
-$1.36B
(-19%)
Cap. Flow
-$72.7M
Cap. Flow
% of AUM
-1.28%
Top 10 Holdings %
Top 10 Hldgs %
17.58%
Holding
1,139
New
165
Increased
376
Reduced
380
Closed
175
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Starbucks
SBUX
|
+$58.3M |
| 2 |
CELG
Celgene Corp
CELG
|
+$27.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$23.3M |
| 4 |
TJX Companies
TJX
|
+$23.1M |
| 5 |
Synopsys
SNPS
|
+$19.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dell
DELL
|
+$45.2M |
| 2 |
Rockwell Automation
ROK
|
+$25.3M |
| 3 |
Accenture
ACN
|
+$24M |
| 4 |
Visteon
VC
|
+$23.4M |
| 5 |
ARRS
ARRIS International plc Ordinary Shares
ARRS
|
+$22.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.85% |
| 2 | Financials | 17.71% |
| 3 | Consumer Discretionary | 12.6% |
| 4 | Healthcare | 11.49% |
| 5 | Industrials | 11.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VVUS
926
DELISTED
Vivus Inc
VVUS
| $132K | ﹤0.01% |
59,044
+13,575
| +30% | +$46.8K |
|
|
FTSI
927
DELISTED
FTS International, Inc. Common Stock
FTSI
| $130K | ﹤0.01% |
+915
| New | +$193K |
|
|
PFSW
928
DELISTED
PFSweb, Inc.
PFSW
| $130K | ﹤0.01% |
25,310
-7,640
| -23% | -$49.1K |
|
|
MSL
929
DELISTED
Midsouth Bancorp, Inc.
MSL
| $128K | ﹤0.01% |
+12,063
| New | +$159K |
|
930
Universal Technical Institute
UTI
$2.08B
| $127K | ﹤0.01% |
+34,925
| New | +$99.2K |
|
|
CPRX
931
DELISTED
Catalyst Pharmaceutical
CPRX
| $125K | ﹤0.01% |
+65,200
| New | +$187K |
|
|
OMED
932
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $120K | ﹤0.01% |
160,244
+75,514
| +89% | +$114K |
|
|
LITS
933
Lite Strategy Inc
LITS
$33.6M
| $116K | ﹤0.01% |
2,204
-5,222
| -70% | -$322K |
|
|
CFMS
934
DELISTED
Conformis, Inc. Common Stock
CFMS
| $115K | ﹤0.01% |
12,875
+1,824
| +17% | +$30.7K |
|
935
Orion Group Holdings
ORN
$514M
| $113K | ﹤0.01% |
26,416
-39,275
| -60% | -$197K |
|
936
Key Tronic
KTCC
$40.3M
| $110K | ﹤0.01% |
19,433
| – | – |
|
937
SandRidge Energy
SD
$510M
| $108K | ﹤0.01% |
14,200
| – | – |
|
|
CNST
938
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $108K | ﹤0.01% |
+26,919
| New | +$162K |
|
939
Zevra Therapeutics
ZVRA
$563M
| $106K | ﹤0.01% |
3,722
+1,363
| +58% | +$55.2K |
|
|
PETX
940
DELISTED
Aratana Therapeutics, Inc.
PETX
| $105K | ﹤0.01% |
17,100
-50,724
| -75% | -$310K |
|
|
OTIC
941
DELISTED
Otonomy, Inc.
OTIC
| $104K | ﹤0.01% |
56,309
+7,098
| +14% | +$16.7K |
|
942
Titan International
TWI
$516M
| $100K | ﹤0.01% |
+21,400
| New | +$139K |
|
943
Spero Therapeutics
SPRO
$68.9M
| $95K | ﹤0.01% |
15,440
-1,083
| -7% | -$8.77K |
|
944
IRIDEX
IRIX
$15.5M
| $90K | ﹤0.01% |
19,063
-700
| -4% | -$3.48K |
|
|
SREV
945
DELISTED
ServiceSource International, Inc.
SREV
| $87K | ﹤0.01% |
80,525
-197,213
| -71% | -$310K |
|
946
Ceco Environmental
CECO
$4.42B
| $85K | ﹤0.01% |
+12,578
| New | +$96.3K |
|
947
IDT Corp
IDT
$1.6B
| $82K | ﹤0.01% |
13,200
-12,900
| -49% | -$92K |
|
|
VOXX
948
DELISTED
VOXX International Corporation Class A
VOXX
| $81K | ﹤0.01% |
20,383
-134,498
| -87% | -$669K |
|
949
Riverview Bancorp
RVSB
$107M
| $79K | ﹤0.01% |
+10,900
| New | +$87.5K |
|
|
NH
950
DELISTED
NantHealth, Inc
NH
| $78K | ﹤0.01% |
9,614
-54
| -0.6% | -$946 |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q4 2018 Portfolio in Review
As of Q4 2018, Jacobs Levy Equity Management held 1,139 positions worth $5.69B, down 19% from $7.05B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jacobs Levy Equity Management's Q4 2018 filing shows 165 new, 376 increased, 380 reduced and 175 closed positions. Its largest new stake was Starbucks: 930,980 shares worth $60M. The largest sale was Dell, an estimated $45.2M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
- Jacobs Levy Equity Management's largest Q4 2018 buy was Starbucks: 930,980 shares worth $60M.
- Jacobs Levy Equity Management added most to Celgene Corp in Q4 2018, an estimated $27.6M increase.
- Jacobs Levy Equity Management's biggest Q4 2018 reduction was Accenture, cutting an estimated $24M.
- Jacobs Levy Equity Management fully exited Dell in Q4 2018, selling an estimated $45.2M.
- Jacobs Levy Equity Management's ten largest holdings make up 18% of its $5.69B portfolio in Q4 2018.
- Jacobs Levy Equity Management opened 165 new positions and closed 175 in Q4 2018.
- Jacobs Levy Equity Management's portfolio value fell 19% quarter-over-quarter to $5.69B.
Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.